<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01508988</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-9054IOU001</org_study_id>
    <nct_id>NCT01508988</nct_id>
  </id_info>
  <brief_title>Single Dose Escalation Study of ONO-9054 in Healthy Volunteers</brief_title>
  <official_title>A Double-masked Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ONO-9054 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharma USA Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of ascending
      single doses of ONO-9054 administered as a single drop in healthy adult subjects. The
      secondary objectives are to characterize the pharmacokinetic (PK) profile of ONO-9054 and its
      metabolite in plasma and to evaluate the pharmacodynamic (PD) profile.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of ONO-9054 using vital signs, ECGs, laboratory tests, ocular exams, spirometry, physical examinations and incidence/severity of adverse events</measure>
    <time_frame>up to 4 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Characterization of PK profiles of ONO-9054 and metabolite through measurement of drug concentration in plasma sample</measure>
    <time_frame>up to 2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Pharmacodynamic evaluation of ophthalmic effects by measuring the degree and duration of intraocular pressure lowering</measure>
    <time_frame>up to 2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy Adult Subjects</condition>
  <arm_group>
    <arm_group_label>Eye drops 0.3 µg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eye drops 1 µg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eye drops 3 µg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eye drops 10 µg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eye drops 20 µg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eye drops 30 µg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eye drops placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-9054</intervention_name>
    <description>Eye drops 0.3 µg/mL both eyes on Day one</description>
    <arm_group_label>Eye drops 0.3 µg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-9054</intervention_name>
    <description>Eye drops 1 µg/mL both eyes on Day one</description>
    <arm_group_label>Eye drops 1 µg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-9054</intervention_name>
    <description>Eye drops 3 µg/mL both eyes on Day one</description>
    <arm_group_label>Eye drops 3 µg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-9054</intervention_name>
    <description>Eye drops 10 µg/mL both eyes on Day one</description>
    <arm_group_label>Eye drops 10 µg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-9054</intervention_name>
    <description>Eye drops 20 µg/mL both eyes on Day one</description>
    <arm_group_label>Eye drops 20 µg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-9054</intervention_name>
    <description>Eye drops 30 µg/mL both eyes on Day one</description>
    <arm_group_label>Eye drops 30 µg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-9054</intervention_name>
    <description>Matched-placebo eye drops dosed in the same manner as ONO-9054 in both eyes on Day one</description>
    <arm_group_label>Eye drops placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects, aged 18-64 inclusive

          -  Body mass index (BMI) of 19-35 kg/m2 (inclusive)

          -  IOP measurement oculus uterque (OU, both eyes) &lt; 21 mm Hg (inclusive) at screening and
             Day -1

          -  Best corrected visual acuity (BCVA) 20/30 or better (Snellen Equivalent) at both the
             screening visit and Day -1

        Exclusion Criteria:

          -  Any history of severe ocular trauma in either eye at any time

          -  Any history of previous intraocular or ocular laser surgery within the past 3 months
             or any refractive surgery procedure within the past 6 months of the screening visit in
             either eye

          -  Current or chronic history of ocular infection within the past 3 months of screening
             visit in either eye OR ongoing or recurrent ocular inflammation in either eye

          -  At the ophthalmic investigator's discretion, any subjects who have a history of any
             significant ocular conditions in either eye that would contraindicate the use of the
             study medication, or that might affect the study conduct, or the interpretation of the
             study results

          -  Use of any non-diagnostic topical ophthalmic solutions except for sponsor-recommended
             tear substitutes from admission to the study unit through the duration of the study

          -  History of clinically significant drug or food allergy, positive HIV, hepatitis B or C
             at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ono Pharma USA, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Phase 1 Unit</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2012</study_first_submitted>
  <study_first_submitted_qc>January 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2012</study_first_posted>
  <last_update_submitted>June 12, 2012</last_update_submitted>
  <last_update_submitted_qc>June 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ONO-9054</keyword>
  <keyword>adult healthy volunteers</keyword>
  <keyword>single dose</keyword>
  <keyword>phase 1</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

